Surgical excision versus topical 5% 5-fluorouracil and photodynamic therapy in the treatment of Bowen&apos;s disease: long-term results of a multicenter randomized controlled trial

Rheumatoid Arthritis

Treatment with methotrexate plus oral prednisolone versus triple therapy (methotrexate/sulfasalazine/hydroxychloroquine) plus intra-articular glucocorticoids in early rheumatoid arthritis: a prespecified nonrandomised subgroup analysis of clinical and radiographic data at 48 weeks from the NORD-STAR trial's conventional treatment arm

Ann Rheum Dis

Hetland ML, Heiberg MS, Sokka-Isler T, Rudin A, Østergaard M, Haavardsholm E, Rutanen J, van Vollenhoven R, Grondal G, Ørnbjerg LM, Bøyesen P, Lampa J, Nurmohamed M, Gudbjornsson B, Uhlig T, Kononoff A, Lend K, Krabbe S, Olsen IC, Sexton J, Hørslev-Petersen K

doi: 10.1016/j.ard.2025.03.002

Melanoma and Skin Cancer

Red light photodynamic therapy with 10% aminolevulinic acid gel showed efficacy for treatment of superficial basal cell carcinoma in a randomized, vehicle controlled, double-blind, multicenter phase III study

J Am Acad Dermatol

Schlesinger T, Chapman MS, Tu JH, Cohen JL, Strasswimmer J, Zeitouni NC, Torres A, Jazayeri SS, Goldman MP, Ibrahim SF, Lain EL, Couvillion MP, Bruce S, Laquer VT, Hanke CW, Ozog DM, Schneider J, Markowitz O, Berman B, Nestor MS, Gold MH, Munavalli GS, Forsha DW, Siegel DM, Mrohs D, Schmitz B, Schäning R, Pospiech N, Lyons J, Foguet M, Lübbert M, Lübbert H, Pariser DM

doi: 10.1016/j.jaad.2025.08.031

Vitiligo

Comparative Efficacy of Topical Tofacitinib versus Topical Tacrolimus in the Treatment of localized Vitiligo: A Randomized, Investigator-Blinded, Intraindividual Trial

Br J Dermatol

Mehta H, Bishnoi A, Parsad D, Kumaran MS, Vinay K

doi: 10.1093/bjd/ljaf306

Autoimmune Disease

Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis : A Randomized Controlled Trial

Ann Intern Med

Terrier B, Pugnet G, de Moreuil C, Bonnotte B, Benhamou Y, Chauveau D, Besse MC, Duffau P, Limal N, Néel A, Urbanski G, Jourde-Chiche N, Martin-Silva N, Campagne J, Mekinian A, Schleinitz N, Ackermann F, Fauchais AL, Froissart A, Le Gallou T, Uzunhan Y, Viallard JF, Bérezné A, Chiche L, Taillé C, Direz G, Durel CA, Godmer P, Trad S, Lambert M, de Menthon M, Quéméneur T, Cadranel J, Charles P, Dossier A, Jilet L, Guillevin L, Abdoul H, Puéchal X, French Vasculitis Study Group

doi: 10.7326/ANNALS-24-03947

Rheumatoid Arthritis

Long-term comparative analysis of secukinumab versus TNFα inhibitors in patients with spondyloarthritis: treatment persistence is differentially affected by disease phenotype, obesity and sex

Arthritis Res Ther

Flouri ID, Repa A, Avgoustidis N, Pitsigavdaki S, Kalogiannaki E, Kalligianni-Sofikiti K, Emmanouilidou E, Marolachaki E, Bertsias G, Sidiropoulos P

doi: 10.1186/s13075-025-03664-y

Autoimmune Disease

A systematic review of clinical trial designs and outcome measures in Sjögren's disease randomized trials

J Rheumatol

Beydon M, Nguyen Y, Gordon R, Foulquier N, Bouillot C, Hammitt KM, Bowman SJ, Mariette X, Cornec D, McCoy SS, Seror R

doi: 10.3899/jrheum.2024-1012

Vitiligo

Oral tofacitinib in comparison with dexamethasone oral mini-pulse therapy for the treatment of active nonsegmental vitiligo: A randomized controlled trial

J Am Acad Dermatol

Dev A, Vinay K, Bishnoi A, Kumaran MS, Mehta H, Parsad D

doi: 10.1016/j.jaad.2025.06.006

Autoimmune Disease

Transcriptomic stratification predicts response to rituximab, abatacept, or the association of hydroxychloroquine and leflunomide in 3 randomised controlled clinical trials of Sjögren's disease

Ann Rheum Dis

Chevet B, Devauchelle-Pensec V, Pontarini E, Baloche V, Bombardieri M, Bowman SJ, Barnes M, Sreih AG, Liu J, Kelly S, Christodoulou A, Moingeon P, Laigle L, Soret P, Le Dantec C, Pers JO, Alarcon-Riquelme ME, Barturen G, Mariette X, van Roon J, Seror R, Nocturne G, Cornec D, Foulquier N, PRECISEADS Clinical Consortium, NECESSITY consortium

doi: 10.1016/j.ard.2025.11.017

Acne

Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension

J Am Acad Dermatol

Sayed CJ, Kirby B, Garg A, Naik HB, Kimball AB, Zouboulis CC, Jemec GBE, Kokolakis G, Ingram JR, Morita A, Deherder D, Crater C, Rolleri RL, Vaux T, Lambert J, Lukowski B, Bechara FG

doi: 10.1016/j.jaad.2025.11.031

Dermatology · Immunology · Rheumatology

Surgical excision versus topical 5% 5-fluorouracil and photodynamic therapy in the treatment of Bowen's disease: long-term results of a multicenter randomized controlled trial

Related content

Red light photodynamic therapy with 10% aminolevulinic acid gel showed efficacy for treatment of superficial basal cell carcinoma in a randomized, vehicle controlled, double-blind, multicenter phase III study

Comparative Efficacy of Topical Tofacitinib versus Topical Tacrolimus in the Treatment of localized Vitiligo: A Randomized, Investigator-Blinded, Intraindividual Trial

Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis : A Randomized Controlled Trial

Long-term comparative analysis of secukinumab versus TNFα inhibitors in patients with spondyloarthritis: treatment persistence is differentially affected by disease phenotype, obesity and sex

A systematic review of clinical trial designs and outcome measures in Sjögren's disease randomized trials

Oral tofacitinib in comparison with dexamethasone oral mini-pulse therapy for the treatment of active nonsegmental vitiligo: A randomized controlled trial

Transcriptomic stratification predicts response to rituximab, abatacept, or the association of hydroxychloroquine and leflunomide in 3 randomised controlled clinical trials of Sjögren's disease

Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension